Costa, RitaAntunes, PaulaSalvador, PedroOliveira, PedroMarinho, António2023-11-162023-11-162021-08Costa R, Antunes P, Salvador P, Oliveira P, Marinho A. Secukinumab on Refractory Lupus Nephritis. Cureus. 2021;13(8):e17198. Published 2021 Aug 15. doi:10.7759/cureus.171982168-8184http://hdl.handle.net/10400.16/2891Lupus nephritis (LN) is the most frequent severe organ manifestation of systemic lupus erythematosus (SLE). About 30% of patients are refractory to treatment. The authors report a case of treatment of LN with interleukin-17-targeted therapy, demonstrating its possible benefit, after reports of T helper 17 cell involvement in SLE pathogenesis. We present the case of a childbearing age woman with SLE, who developed refractory LN despite all the indicated therapeutic options. During follow up, infection with human papillomavirus was detected, a possible trigger, and the following management was based on this discovery. We currently know that cytokines play a major role in tissue damage and interleukin-17 (IL-17) seems to be a fundamental key in SLE and LN, having shown its expression in renal glomeruli and urinary sediment. Thus, it was decided to start treatment with an anti-IL-17A antibody, secukinumab. After starting secukinumab, clinical and biological features improved and complete renal response was achieved.engcytokinesil-17 inhibitor therapyimmunosuppressive therapylupus nephritisproteinuriasecukinumabsystemic lupus erythematosusth17 cellsjournal article10.7759/cureus.17198